Dexfenfluramine Articles
Indian Health Ministry bans obesity drug rimonabant following reports of side effects; TB drug curb moves “a failure”
4 January 2010
Locaserin trial passes 1-year safety review
31 March 2008
Servier pays up over Redux/Ponderal in Canada
6 June 2005
Manhattan's obesity drug: strong results
6 June 2005
Servier will pay to avoid legal action
27 September 2004
Wyeth wins multiple Philadelpha diet drug cases
23 August 2004
European court overturns obesity drug ban
3 February 2003
Servier in court for Isomeride compensation
1 April 2002
AHP changes name to Wyeth
18 March 2002
AHP overcomes fen-phen problems to post strong growth for 2001
4 February 2002
AHP takes $950 mill fen-phen charge
24 October 2001
AHP still pursued by fen-phen specter
11 September 2001
AHP and Interneuron bury diet drug hachet
1 June 2001
AHP takes $7.5 billion charge for fen-phen
26 January 2001
Ruling permits obesity drug class action
24 November 2000
Decision time ahead for Servier in legal action over Isomeride
22 November 2000
AHP reaping benefits of R&D spend
20 October 2000
AHP posts healthy 2nd quarter results
24 July 2000
AHP posts 18% net income growth
20 April 2000
AHP going ahead with fen-phen settlement
17 April 2000
Antiobesity drugs to be banned in EU
6 April 2000
Antiobesity drugs to be banned in EU
31 March 2000
Interneuron sues AHP over "fen-phen" data
27 January 2000
Healthy full-year results for many US pharmaceutical companies
27 January 2000
Interneuron crashes again as citicoline fails in stroke
13 January 2000
Interneuron surges on pagoclone license
29 December 1999
AHP diet drug settlement approved
25 November 1999
Xenical, Meridia drive US antiobesity drugmarket
15 November 1999
American Home Products confirms merger talks with Warner-Lambert
3 November 1999
AHP settling fen-phen cases in California
11 October 1999
CPMP seeks ban on phentermine, etc
29 September 1999
Stock Commentary New York
23 September 1999
BASF Pharma hoping to catch up with top pharmaceutical companies
23 September 1999
AHP weathers the storm with first Rapamune approval
17 September 1999
AHP close to settling $3 billion lawsuits?
17 September 1999
Stock Commentary New York
16 September 1999
Stock Commentary New York
22 July 1999
Charges against AHP executives dismissed
22 February 1999
New UK obesity guidelines highlight role of drugs
25 January 1999
FDA's "Lower Standards Are Jeopardizing Health"
14 December 1998
Servier Invests In Brazil
11 December 1998
Healthy Third-Quarter Growth For US Drug Majors
22 October 1998
US FDA Proposed Rule On Banned Drugs
13 October 1998
Interneuron Settles Redux Lawsuits For $70 Million
8 September 1998
Phentermine To Blame for Fen-Phen Side Effects?
1 September 1998
First European Launch Of Xenical In September
4 August 1998
NIH Obesity Guidelines Define Role Of Drugs
25 June 1998
Wyeth Withdraws Duract Due To Serious Liver Events
24 June 1998
USA's Most-Dispensed Rx Drugs In April 1998
20 May 1998
US Quarterly Financial Results Round-Up
23 April 1998
Interneuron's CerAxon To Be Fast-Tracked
8 April 1998
Stock Commentary New York
8 April 1998
Redux Study Casts Doubt On Valve Disease Problem
1 April 1998
Panel Split On Orlistat Approval For Obesity
16 March 1998
Strong Growth For US Drug Firms In 1997
28 January 1998
SB Exec Casts Doubts On AHP Merger
27 January 1998
SmithKline Beecham/American Home "Talks On"
22 January 1998
SmithKline Beecham/American Home "Talks On"
21 January 1998
"No Comment" On SB/AHP Tie-Up Rumors
19 January 1998
Knoll's High Hopes For Its Obesity Drug Sibutramine
15 January 1998
US Approval For Knoll's Obesity Drug Meridia
27 November 1997
Euro CPMP Plenary Meeting In October
12 November 1997
FDA Post-Marketing Surveillance Funding
11 November 1997
Stock Commentary New York
7 November 1997
US 3rd Quarter Results Show Strong Growth
22 October 1997
Italian Pharma Commission Backs Move On Laxatives
20 October 1997
American Home Doesn't Fear Diet Pill Law Suits
6 October 1997
Servier Defends Dietary Drugs
24 September 1997
Wyeth-Ayerst Recalls Redux And Pondimin
17 September 1997
Wyeth To Begin Redux Neurotoxicity Study
4 September 1997
Roche Share Price Dips On Xenical delay
29 August 1997
Wyeth To Study Redux' Cognitive Effects
22 August 1997
US Drug & Biotech Firms Post Quarterly Results
14 August 1997
Heart Disease Link To Diet Drugs Prompts FDA Action
15 July 1997
New Antiobesity Drug Regulations In UK
30 May 1997
Higher Biotech Earnings But Investors Stay Cool
19 May 1997
Roche Nearer To Obesity Drug Approval
19 May 1997
Sales Slip At American Home Products
5 May 1997
Obesity Drug Sales Show Strong Rise In January
24 March 1997
Two Worlds For Servier: USA And France
17 March 1997
Interneuron Pharma's First Quarter
24 February 1997
Roche Enters New Product Phase With Bright Prospects
17 February 1997
Serotonin And Satiety: Targets For Drug Discovery
27 January 1997
Excellent Year For The Biotechnology Industry
16 December 1996
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
